Amphetamine toxicity in the emergency department

European Journal of Emergency Medicine

Volumn 12, Issue 4, 2005, Pages 193-197

  Smets, Gert ^a   Bronselaer, Koen ^a   De Munnynck, Katja ^a   De Feyter, Koen ^a   Van de Voorde, Wim ^a   Sabbe, Marc ^a  

^a LICOS Centre for Institutions and Economic Performance   (United States)

Author keywords

Acute poisoning; Amphetamines; Keywords; XTC

Indexed keywords

3,4 METHYLENEDIOXYAMPHETAMINE; 3,4 METHYLENEDIOXYETHAMPHETAMINE; 3,4-METHYLENEDIOXYETHAMPHETAMINE; 4 METHYLTHIOAMPHETAMINE; 4-METHYLTHIOAMPHETAMINE; AMPHETAMINE DERIVATIVE; DRUG DERIVATIVE;

ADDICTION; ADULT; ARTICLE; CASE REPORT; EMERGENCY HEALTH SERVICE; FATALITY; FEMALE; HUMAN; MALE;

3,4-METHYLENEDIOXYAMPHETAMINE; ADULT; AMPHETAMINES; EMERGENCY SERVICE, HOSPITAL; FATAL OUTCOME; FEMALE; HUMANS; MALE; SUBSTANCE-RELATED DISORDERS;

EID: 32944474171     PISSN: 09699546     EISSN: 14735695     Source Type: Journal    
DOI: 10.1097/00063110-200508000-00010     Document Type: Article

References (57)

1. Martin TL. Three cases of fatal paramethoxyamphetamine overdose. J Anal Toxicol 2001; 25:649-651.
2. Green A, Richard ea. The pharmacology and clinical pharmacology of 3,4-methylendioxymethamphetamine (MDMA, ecstasy). Pharmacol Rev 2003; 55:463-508.
3. Iravani MM, Asari D, Patel J, Wieczorek WJ, Kruk ZL. Direct effects of 3,4-methylenedioxymethamphetamine (MDMA) on serotonin or dopamine release and uptake in the caudate putamen, nucleus accumbens, substantia nigra pars reticulata, and the dorsal raphe nucleus slices. Synapse 2000; 36:275-285.
4. Green AR, Cross AJ, Goodwin GM. Review of the pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA or ‘ecstasy’). Psychopharmacology (Berl) 1995; 119:247-260.
5. Liechti ME, Baumann C, Gamma A, Vollenweider FX. Acute psychological effects of 3,4-methylenedioxymethamphetamine (MDMA, ‘ecstasy’) are attenuated by the serotonin uptake inhibitor citalopram. Neuropsychopharmacology 2000; 22:513-521.
6. Green AL, El Hait MA. P-methoxamphetamine, a potent reversible inhibitor of type-A monoamine oxidase in vitro and in vivo. J Pharm Parmacol 1980; 32:262-266.
7. Cohen RS. Subjective reports on the effects of the MDMA (‘ecstasy’) experience in humans. Prog Neuropsychopharmacol Biol Psychiatry 1995; 19:1137-1145.
8. Harris DS, Baggott M, Mendelson JH, Mendelson JE, Jones RT. Subjective and hormonal effects of 3,4-methylenedioxymethamphetamine (MDMA) in humans. Psychopharmacology (Berl) 2002; 162:396-405.
9. Selmi F, Davies KG, Sharma RR, Neal JW. Intracerebral haemorrhage due to amphetamine abuse: report of two cases with underlying arteriovenous malformations. Br J Neurosurg 1995; 9:93-96.
10. McEvoy AW, Kitchen ND, Thomas DG. Intracerebral haemorrhage and drug abuse in young adults. Br J Neurosurg 2000; 14:449-454.
11. Auer J, Berent R, Weber T, Lassnig E, Eber B. Subarachnoid haemorrhage with ‘ecstasy’ abuse in a young adult. Neurol Sci 2002; 23:199-201.
12. Buxton N, McConachie NS. Amphetamine abuse and intracranial haemorrhage. J R Soc Med 2000; 93:472-477.
13. Matick HAD, Brumlik J. Cerebral vasculitis associated with oral amphetamine overdose. Arch Neurol 1983; 40:253-254.
14. Schteinschnaider A, Plaghos LL, Garbugino S, Riveros D, Lazarowski A, Intruvini S. Cerebral arteritis following methylphenidate use. J Child Neurol 2000; 15:265-267.
15. O’Shea E, Granados R, Esteban B, Colado MI, Green AR. The relationship between the degree of neurodegeneration of rat brain 5-HT nerve terminals and the dose and frequency of administration of MDMA (‘ecstasy’). Neuropharmacology 1998; 37:919-926.
16. Boot BP, McGregor IS, Hall W. MDMA (ecstasy) neurotoxicity: assessing and communicating the risks. Lancet 2000; 355:1818-1821.
17. Colado MI, Granados R, O’Shea E, Esteban B, Green AR. The acute effect in rats of 3,4-methylenedioxyethamphetamine (MDEA, ‘eve’) on body temperature and long term degeneration of 5-HT neurones in brain: a comparison with MDMA (‘ecstasy’). Pharmacol Toxicol 1999; 84:261-216.
18. Ricaurte GA, Yuan J, McCann UD. (+/-)3,4-Methylenedioxymethamphetamine (‘ecstasy’)-induced serotonin neurotoxicity: studies in animals. Neuropsychobiology 2000; 42:5-10.
19. Wilkins B. Cerebral oedema after MDMA (‘ecstasy’) and unrestricted water intake. Hyponatraemia must be treated with low water input. Brit med j 1996; 313:689-690 (author reply, 690).
20. Magee C, Staunton H, Tormey W, Walshe JJ. Hyponatraemia, seizures and stupor associated with ecstasy ingestion in a female. Ir Med J 1998; 91:178.
21. O’Connor A, Cluroe A, Couch R, Galler L, Lawrence J, Synek B. Death from hyponatraemia-induced cerebral oedema associated with MDMA (‘ecstasy’) use. NZ Med J 1999; 112:255-256.
22. Holmes SB, Banerjee AK, Alexander WD. Hyponatraemia and seizures after ecstasy use. Postgrad Med J 1999; 75:32-23.
23. Mas M, Farre M, de la Torre R, Roset PN, Ortune J, Segura J, et al. Cardiovascular and neuroendocrine effects and pharmacokinetics of 3, 4-methylenedioxymethamphetamine in humans. J Pharmacol Exp Ther 1999; 290:136-145.
24. Ghuran A, Nolan J. Recreational drug misuse: issues for the cardiologist. Heart 2000; 83:627-633.
25. Bashour TT. Acute myocardial infarction resulting from amphetamine abuse: a spasm-thrombus interplay? Am Heart J 1994; 128:1237-1239.
26. Costa GM, Pizzi C, Bresciani B, Tumscitz C, Gentile M, Bugiardini R. Acute myocardial infarction caused by amphetamines: a case report and review of the literature. Ital Heart J 2001; 2:478-480.
27. Hung MJ, Kuo LT, Cherng WJ. Amphetamine-related acute myocardial infarction due to coronary artery spasm. Int J Clin Pract 2003; 57:62-64.
28. Ochoa Gomez FJ, Fernandez Esteban MV, Saralegui Reta I, Rodriguez Garcia JF, Munoz Lafoz MA, Moreno Ortigosa A, et al. Myocardial infarction caused by amphetamine. Ann Med Interna Sp 2001; 18:111.
29. Qasim A, Townend J, Davies MK. Ecstasy induced acute myocardial infarction. Heart 2001; 85:E10.
30. Waksman J, Taylor RN Jr, Bodor GS, Daly FF, Jolliff HA, Dart RC. Acute myocardial infarction associated with amphetamine use. Mayo Clin Proc 2001; 76:323-326.
31. Hong RME. Cardiomyopathy associated with the smoking of crystal methamphetamine. J Am Med Assoc 1991; 255:1152-1154.
32. Bergmeier W, Rackebrandt K, Schroder W, Zirngibl H, Nieswandt B. Structural and functional characterization of the mouse von Willebrand factor receptor GPIb-IX with novel monoclonal antibodies. Blood 2000; 95:886-893.
33. Bingham C, Beaman M, Nicholls AJ, Anthony PP. Necrotizing renal vasculopathy resulting in chronic renal failure after ingestion of methamphetamine and 3,4-methylenedioxymethamphetamine (‘ecstasy’). Nephrol Dial Transplant 1998; 13:2654-2655.
34. Bruce I, McNally J, Bell A. Enhanced monocyte generation of reactive oxygen species in primary systemic vasculitis. J Rheumatol 1997; 24:2364-2370.
35. Woodrow G, Turney JH. Ecstasy-induced renal vasculitis. Nephrol Dial Transplant 1999; 14:798.
36. Cherney DZ, Davids MR, Halperin ML. Acute hyponatraemia and ‘ecstasy’: insights from a quantitative and integrative analysis. QJM 2002; 95:475-483.
37. Sue YM, Lee YL, Huang JJ. Acute hyponatremia, seizure, and rhabdomyolysis after ecstasy use. J Toxicol Clin Toxicol 2002; 40:931-932.
38. Ajaelo I, Koenig K, Snoey E. Severe hyponatremia and inappropriate antidiuretic hormone secretion following ecstasy use. Acad Emerg Med 1998; 5:839-840.
39. Henry JA, Fallon JK, Kicman AT, Hutt AJ, Cowan DA, Forsling M. Low-dose MDMA (‘ecstasy’) induces vasopressin secretion. Lancet 1998; 351:1784.
40. Forsling ML, Fallon JK, Shah D, Tilbrook GS, Cowan DA, Kicman AT, et al. The effect of 3,4-methylenedioxymethamphetamine (MDMA, ‘ecstasy’) and its metabolites on neurohypophysial hormone release from the isolated rat hypothalamus. Br J Pharmacol 2002; 135:649-656.
41. Jones AL, Simpson KJ. Review article: mechanisms and management of hepatotoxicity in ecstasy (MDMA) and amphetamine intoxications. Ailment Pharmacol Ther 1999; 13:129-133.
42. Wu D, Otton SV, Inaba T, Kalow W, Sellers EM. Interactions of amphetamine analogs with human liver CYP2D6. Biochem Pharmacol 1997; 53:1605-1612.
43. Andreu V, Mas A, Bruguera M, Salmeron JM, Moren V, Nogue S, et al. Ecstasy: a common cause of severe acute hepatotoxicity. J Hepatol 1998; 29:394-397.
44. Khakoo SI, Coles CJ, Armstrong JS, Barry RE. Hepatotoxicity and accelerated fibrosis following 3,4-methylenedioxymetamphetamine (‘ecstasy’) usage. J Clin Gastroenterol 1995; 20:244-247.
45. Lawler LP, Abraham S, Fishman EK. 3,4-Methylenedioxymethamphetamine (ecstasy)-induced hepatotoxicity: multidetector CT and pathology findings. J Comput Assist Tomogr 2001; 25:649-652.
46. Selim K, Kaplowitz N. Hepatotoxicity of psychotropic drugs. Hepatology 1999; 29:1347-1351.
47. Fidler H, Dhillon A, Gertner D, Burroughs A. Chronic ecstasy (3,4-methylenedioxymetamphetamine) abuse: a recurrent and unpredictable cause of severe acute hepatitis. J Hepatol 1996; 25:563-566.
48. Callaway CW, Clark RF. Hyperthermia in psychostimulant overdose. Ann Emerg Med 1994; 24:68-76.
49. Bowyer JF. The role of hyperthermia in amphetamine’s interactions with NMDA receptors, nitric oxide, and age to produce neurotoxicity. Ann NY Acad Sci 1995; 765:309-310.
50. Mallick A, Bodenham AR. MDMA induced hyperthermia: a survivor with an initial body temperature of 42.9 degrees C. J Accid Emerg Med 1997; 14:336-338.
51. Pedersen NP, Blessing WW. Cutaneous vasoconstriction contributes to hyperthermia induced by 3,4-methylenedioxymethamphetamine (ecstasy) in conscious rabbits. J Neurosci 2001; 21:8648-8654.
52. Mechan AO, O’Shea E, Elliott JM, Colado MI, Green AR. A neurotoxic dose of 3,4-methylenedioxymethamphetamine (MDMA; ecstasy) to rats results in a long-term defect in thermoregulation. Psychopharmacology (Berl) 2001; 155:413-418.
53. Brown PL, Wise RA, Kiyatkin EA. Brain hyperthermia is induced by methamphetamine and exacerbated by social interaction. J Neurosci 2003; 23:3924-3929.
54. Sprague JE, Banks ML, Cook VJ, Mills EM. Hypothalamic-pituitary-thyroid axis and sympathetic nervous system involvement in hyperthermia induced by 3,4-methylenedioxymethamphetamine (ecstasy). J Pharmacol Exp Ther 2003; 305:159-166.
55. Gudelsky GA, Yamamoto BK. Neuropharmacology and neurotoxicity of 3,4-methylenedioxymethamphetamine. Methods Mol Med 2003; 79:55-73.
56. Kraus T, Gerbershagen MU, Fiege M, Weißhorn F, Wappler F. Dantrolene - a review of its pharmacology, therapeutic use and new developments. Anaesthesia 2004; 59:364-373.
57. Montiel-Duarte C, Ansorena E, Lopez-Zabalza MJ, Cenarruzabeitia E, Iraburu MJ. Role of reactive oxygen species, glutathione and NF-kappaB in apoptosis induced by 3,4-methylenedioxymethamphetamine (‘ecstasy’) on hepatic stellate cells. Biochem Pharmacol 2004; 67:1025-1033.